CVRx, Inc. (CVRX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy
CVRX stock gains after Humana adds Medicare Advantage coverage for Barostim therapy, boosting reimbursement momentum and patient access.
Down 31.7% in 4 Weeks, Here's Why You Should You Buy the Dip in CVRx (CVRX)
CVRx (CVRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
CVRx, Inc. (CVRX) Q1 2026 Earnings Call Transcript
CVRx, Inc. (CVRX) Q1 2026 Earnings Call Transcript
CVRx, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JC Joseph Castro Nuveen LLC | 42,749 | $409,392.14 | $209,042.61 | -$200,349.53 | -48.94% |
| DH Dinan Hu R Squared Ltd | 10,551 | $75,197.65 | $51,594.39 | -$23,603.26 | -31.39% |
 Alexandra Stickelman Root Financial Partners, LLC | 32 | $303 | $156.48 | -$146.52 | -48.36% |
| MS Mark Schafer Police & Firemen's Retirement System of New Jersey | 3,770 | $47,766 | $18,435.3 | -$29,330.7 | -61.4% |
CVRx, Inc. (CVRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has CVRx, Inc. ever had a stock split?
CVRx, Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Kevin Hykes CEO | NASDAQ (NGS) Exchange | 126638105 CUSIP |
| US Country | 206 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
CVRx, Inc. is a commercial-stage medical device company with a primary focus on the development, manufacturing, and commercialization of neuromodulation solutions aimed at treating cardiovascular diseases. Incorporated in the year 2000 and based in Minneapolis, Minnesota, CVRx has positioned itself at the forefront of the medical device industry by targeting a significant need within the cardiovascular disease treatment spectrum. Through its innovative approach, the company seeks to improve the quality of life for patients suffering from severe cardiovascular conditions by leveraging the potential of neuromodulation therapies. CVRx not only serves patients within the United States but also reaches a global audience, including Germany, through a combination of direct sales force, sales agents, and independent distributors, underscoring its commitment to addressing heart failure on a worldwide scale.
Products and Services
- Barostim
Barostim stands out as CVRx, Inc.’s flagship neuromodulation device, designed specifically to offer symptom improvement for patients dealing with heart failure with reduced ejection fraction, commonly referred to as systolic heart failure. By leveraging the advanced mechanism of neuromodulation, Barostim aims at enhancing the quality of life for those afflicted by this debilitating condition, marking a significant milestone in the treatment of heart failure. Its indication for this particular group of patients highlights the company's dedication to filling a critical gap in cardiovascular disease management through innovative technology.
